FI118155B - Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi - Google Patents

Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi Download PDF

Info

Publication number
FI118155B
FI118155B FI932422A FI932422A FI118155B FI 118155 B FI118155 B FI 118155B FI 932422 A FI932422 A FI 932422A FI 932422 A FI932422 A FI 932422A FI 118155 B FI118155 B FI 118155B
Authority
FI
Finland
Prior art keywords
organic
hot
hydroxy
cold
hydroxynaphthoate
Prior art date
Application number
FI932422A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932422A (fi
FI932422A0 (fi
Inventor
Steven Frederick Beach
David William Stuart Latham
Tony Gordon Roberts
Colin Brian Sidgwick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI932422A publication Critical patent/FI932422A/fi
Publication of FI932422A0 publication Critical patent/FI932422A0/fi
Application granted granted Critical
Publication of FI118155B publication Critical patent/FI118155B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI932422A 1990-11-29 1993-05-27 Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi FI118155B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9026005 1990-11-29
GB909026005A GB9026005D0 (en) 1990-11-29 1990-11-29 Drug material suitable for micronisation
GB9102108 1991-11-28
PCT/GB1991/002108 WO1992009557A1 (en) 1990-11-29 1991-11-28 Benzenedimethanol suitable for micronisation

Publications (3)

Publication Number Publication Date
FI932422A FI932422A (fi) 1993-05-27
FI932422A0 FI932422A0 (fi) 1993-05-27
FI118155B true FI118155B (fi) 2007-07-31

Family

ID=10686212

Family Applications (2)

Application Number Title Priority Date Filing Date
FI932422A FI118155B (fi) 1990-11-29 1993-05-27 Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi
FI982081A FI118203B (fi) 1990-11-29 1998-09-28 Menetelmä valmistaa farmaseuttinen 4-hydroksi-a1-[[[6-(4-fenyylibutoksi)-heksyyli]amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti-(hydroksinaftoaatti)suolaa sisältävä annosmuoto

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI982081A FI118203B (fi) 1990-11-29 1998-09-28 Menetelmä valmistaa farmaseuttinen 4-hydroksi-a1-[[[6-(4-fenyylibutoksi)-heksyyli]amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti-(hydroksinaftoaatti)suolaa sisältävä annosmuoto

Country Status (27)

Country Link
US (1) US5380922A (pl)
EP (2) EP0639176B1 (pl)
JP (1) JP3375626B2 (pl)
KR (1) KR100192196B1 (pl)
AT (1) ATE144244T1 (pl)
AU (1) AU644505B2 (pl)
BG (1) BG61340B1 (pl)
CA (1) CA2099586C (pl)
CY (1) CY2009A (pl)
CZ (1) CZ282996B6 (pl)
DE (1) DE69122780T2 (pl)
DK (1) DK0639176T3 (pl)
ES (1) ES2093812T3 (pl)
FI (2) FI118155B (pl)
GB (1) GB9026005D0 (pl)
GR (1) GR3022088T3 (pl)
HK (1) HK78997A (pl)
HU (1) HU218205B (pl)
IE (1) IE914146A1 (pl)
OA (2) OA09861A (pl)
PL (2) PL167976B1 (pl)
RU (2) RU2116293C1 (pl)
SG (1) SG49741A1 (pl)
SK (1) SK281095B6 (pl)
TW (1) TW309425B (pl)
WO (1) WO1992009557A1 (pl)
ZA (1) ZA919401B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
DE60001492T2 (de) 1999-04-14 2003-12-18 Glaxo Group Ltd., Greenford Pharmazeutische aerosolformulierung
AU2001292929A1 (en) 2000-09-26 2002-04-08 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
KR101100614B1 (ko) 2010-09-20 2011-12-29 한국수력원자력 주식회사 농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법
WO2016142582A1 (en) * 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation

Also Published As

Publication number Publication date
CY2009A (en) 1998-02-20
ES2093812T3 (es) 1997-01-01
SG49741A1 (en) 1998-06-15
EP0639176A1 (en) 1995-02-22
KR100192196B1 (en) 1999-06-15
BG97767A (bg) 1994-12-02
FI932422A (fi) 1993-05-27
FI932422A0 (fi) 1993-05-27
GB9026005D0 (en) 1991-01-16
FI982081A (fi) 1998-09-28
IE914146A1 (en) 1992-06-03
ATE144244T1 (de) 1996-11-15
PL167976B1 (pl) 1995-12-30
HK78997A (en) 1997-06-20
JP3375626B2 (ja) 2003-02-10
HU9301568D0 (en) 1993-09-28
CA2099586A1 (en) 1992-05-30
DE69122780D1 (de) 1996-11-21
HUT64219A (en) 1993-12-28
PL169722B1 (pl) 1996-08-30
EP0571669B1 (en) 1996-03-06
SK54593A3 (en) 1993-10-06
EP0639176B1 (en) 1996-10-16
DE69122780T2 (de) 1997-02-20
AU9040291A (en) 1992-06-25
SK281095B6 (sk) 2000-11-07
RU2116293C1 (ru) 1998-07-27
OA10024A (en) 1996-10-14
WO1992009557A1 (en) 1992-06-11
JPH06503082A (ja) 1994-04-07
RU2197475C2 (ru) 2003-01-27
CZ282996B6 (cs) 1997-12-17
EP0571669A1 (en) 1993-12-01
HU218205B (hu) 2000-06-28
OA09861A (en) 1994-08-15
GR3022088T3 (en) 1997-03-31
TW309425B (pl) 1997-07-01
ZA919401B (en) 1992-07-29
US5380922A (en) 1995-01-10
BG61340B1 (en) 1997-06-30
AU644505B2 (en) 1993-12-09
FI118203B (fi) 2007-08-31
CA2099586C (en) 2002-06-25
FI982081A0 (fi) 1998-09-28
CZ101993A3 (en) 1994-01-19
DK0639176T3 (da) 1996-12-23

Similar Documents

Publication Publication Date Title
US9708300B2 (en) Amorphous form of vilazodone hydrochloride and process for its preparation
JP2650807B2 (ja) 複素環式化合物
JPH11503448A (ja) 吸引可能粒子の製造法
RU2578606C2 (ru) Полиморфные формы соединения st-246 и способы получения
JP2001525850A (ja) ブデソニドの粉砕した結晶粒子を含む組成物
US20150283249A1 (en) Amorphous form of apremilast
FI118155B (fi) Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi
EP2825539A1 (en) Amorphous form of linagliptin and process for preparation thereof
WO2016193994A1 (en) Amorphous selexipag and process for preparation thereof
AP323A (en) Drug material suitable for micronisation.
WO1993016031A1 (en) Benzenedimethanol derivative suitable for micronisation
EP2303232B1 (en) Micronisable form of salmeterol xinafoate
IL101798A (en) 1-hydroxy-2-naphthalene carboxylate (hydroxynaphthoate) salt of 4-hydroxy- alpha1-[[[6-4-phenylbutoxy) hexyl] amino] methyl]-1,3-benzenedimethanol suitable for micronisation
CN1056974C (zh) 适宜于微粒化的药物材料的制备方法
SI9200252A (sl) Zdravilni material, primeren za mikronizacijo
NZ240788A (en) 1-hydroxy-2-naphthalene carboxylate salt of 4-hydroxy- alpha 1

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118155

Country of ref document: FI

MA Patent expired